Skip to main content
NSRX logo

Nasus Pharma Ltd.

NSRXNYSEAMERICANHealthcareDrug Manufacturers - General

$3.18Today:- (-)1Y −59.58%

As of Oct 16, 2026 close

Market cap
$35.04M
P/E (TTM)
-
Forward P/E
-
Dividend yield
-
52-week range
$1.98$9.50
Volume (live)
-
Avg. volume (3M)
18.77K

Nasus Pharma (NSRX) Cash Flow Statement

In fiscal 2025 (fiscal year ended Dec 31, 2025), Nasus Pharma used $4.92M of cash in operating activities and spent $14.00K on capital expenditures. That left free cash flow of −$4.93M.

Nasus Pharma Cash Flow Statement Analysis

Values in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Nasus Pharma Ltd. (NSRX) - Annual data in millions USD
BreakdownFY 2025FY 2024FY 2023FY 2022
Period endingDec 2025Dec 2024Dec 2023Dec 2022
Operating Activities
Net Income-5.86-1.53-1.05-1.71
Stock Based Compensation0.450.010.040.02
Change in Working Capital-0.420.410.170.48
Change in Accounts Payable0.150.00-0.120.15
Change in Other Working Capital-0.450.03-0.040.02
Other Operating Activities0.970.03-0.140.02
Net Cash from Operating Activities-4.92-0.67-1.03-1.21
Investing Activities
Capital Expenditures-0.01---
Purchases of Investments-3.00---
Other Investing Activities-3.00---0.16
Net Cash from Investing Activities-3.01---0.16
Financing Activities
Debt Repayment0.44---
Common Stock Issued8.491.001.000.00
Other Financing Activities0.00-0.23--0.23
Net Cash from Financing Activities8.920.771.061.24
Summary
Effect of Forex Changes on Cash-0.010.000.01-0.01
Net Change in Cash0.980.100.04-0.14
Cash at Beginning of Period0.310.210.170.31
Cash at End of Period1.290.310.210.17
Free Cash Flow-4.93-0.67-1.03-1.21

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Nasus Pharma Cash Flow

What is Nasus Pharma's free cash flow?

Nasus Pharma had negative free cash flow of $4.93M in fiscal 2025 (fiscal year ended Dec 31, 2025), operating cash flow of −$4.92M minus $14.00K of capital expenditures.

How much does Nasus Pharma spend on capital expenditures?

Nasus Pharma spent $14.00K on capital expenditures in fiscal 2025.

Does Nasus Pharma pay dividends or buy back shares?

Nasus Pharma's cash flow statement for fiscal 2025 shows no dividend payments or share repurchases.

What is free cash flow?

Free cash flow is operating cash flow minus capital expenditures. It is the cash a company has left for dividends, buybacks, debt repayment or acquisitions after funding its operations and investment. Full definition